263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data...
15 Kesä 202339min
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why the company believes drug pricing negotiation is “tantamount to extortion." We als...
8 Kesä 202329min
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants and the warped system that made the scam lucrative. We’ll also preview the year’...
1 Kesä 202331min
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
As hospitals and health care companies are racing to implement large language models like ChatGPT into their businesses, STAT reporter Casey Ross joins us to explain what experts want the world to kno...
25 Touko 202331min
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug i...
18 Touko 202340min
258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed results. We also explain what is a massive week for Sar...
11 Touko 202331min
257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business
Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications, and the backstory of what could be a blockbuster ...
4 Touko 202334min
256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent — and why the pharmaceutical industry is fighting it...
27 Huhti 202328min
